Literature DB >> 19541819

Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Thomas J Raife1, Wenjing Cao, Bonnie S Atkinson, Bruce Bedell, Robert R Montgomery, Steven R Lentz, George F Johnson, X Long Zheng.   

Abstract

The function of von Willebrand factor (VWF) is regulated by proteolysis, which limits its multimeric size and ability to tether platelets. The importance of ADAMTS13 metalloprotease in VWF regulation is demonstrated by the association between severe deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura (TTP). However, ADAMTS13 activity levels do not always correlate with the clinical course of TTP, suggesting that other proteases could be important in regulating VWF. We identified 4 leukocyte proteases that cleave the synthetic VWF substrate FRETS-VWF73 and multimeric VWF. Elastase and proteinase 3 (PR3) cleave multimeric VWF and FRETS-VWF73 at the V(1607)-T(1608) peptide bond; cathepsin G and matrix metalloprotease 9 cleave VWF substrates at the Y(1605)-M(1606) and M(1606)-V(1607) bonds, respectively. Isolated intact human neutrophils cleave FRETS-VWF73 at the V(1607)-T(1608) peptide bond, suggesting that elastase or PR3 expressed on leukocyte surfaces might cleave VWF. In the presence of normal or ADAMTS13-deficient plasma, cleavage of FRETS-VWF73 by resting neutrophils is abolished. However, activated neutrophils retain proteolytic activity toward FRETS-VWF73 in the presence of plasma. Although the in vivo relevance remains to be established, these studies suggest the existence of a "hot spot" of VWF proteolysis in the VWF A2 domain, and support the possibility that activated leukocytes may participate in the proteolytic regulation of VWF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541819      PMCID: PMC2731642          DOI: 10.1182/blood-2009-01-195461

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Fluorescence quenching: A tool for single-molecule protein-folding study.

Authors:  X Zhuang; T Ha; H D Kim; T Centner; S Labeit; S Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Proteolytic cleavage of human von Willebrand factor induced by enzyme(s) released from polymorphonuclear cells.

Authors:  E A Thompson; M A Howard
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

3.  Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases.

Authors:  H M Tsai; R L Nagel; V B Hatcher; I I Sussman
Journal:  Biochem Biophys Res Commun       Date:  1989-02-15       Impact factor: 3.575

4.  Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro.

Authors:  E J Campbell; R M Senior; J A McDonald; D L Cox
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

5.  Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway.

Authors:  E F Plow
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

6.  Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease.

Authors:  S D Berkowitz; H Nozaki; K Titani; T Murachi; E F Plow; T S Zimmerman
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

7.  Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders.

Authors:  W Tatewaki; H Takahashi; A Shibata
Journal:  Clin Lab Haematol       Date:  1988

8.  Acquired von Willebrand's disease in the myeloproliferative syndrome.

Authors:  U Budde; G Schaefer; N Mueller; H Egli; J Dent; Z Ruggeri; T Zimmerman
Journal:  Blood       Date:  1984-11       Impact factor: 22.113

9.  Pericellular proteolysis by neutrophils in the presence of proteinase inhibitors: effects of substrate opsonization.

Authors:  E J Campbell; M A Campbell
Journal:  J Cell Biol       Date:  1988-03       Impact factor: 10.539

10.  Elastase-mediated fibrinogenolysis by chemoattractant-stimulated neutrophils occurs in the presence of physiologic concentrations of antiproteinases.

Authors:  J I Weitz; A J Huang; S L Landman; S C Nicholson; S C Silverstein
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

View more
  44 in total

1.  Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils.

Authors:  Christopher J Kuckleburg; Sarah B Tilkens; Sentot Santoso; Peter J Newman
Journal:  J Immunol       Date:  2012-01-20       Impact factor: 5.422

2.  Neutrophils release brakes of coagulation.

Authors:  Wolfram Ruf; Zaverio M Ruggeri
Journal:  Nat Med       Date:  2010-08       Impact factor: 53.440

3.  A model for single-substrate trimolecular enzymatic kinetics.

Authors:  Wei Chen; Cheng Zhu
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

4.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

5.  Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients.

Authors:  Dandan Zhang; Juan Xiao; Haoliang Huang; Juanjuan Chen; Tao Liu; Zongzhi Yin; Danping Gao; Qiong Liu; Jihui Ai; Suhua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

6.  In vivo imaging analysis of the interaction between unusually large von Willebrand factor multimers and platelets on the surface of vascular wall.

Authors:  Miroslaw Rybaltowski; Yuko Suzuki; Hideo Mogami; Iwona Chlebinska; Tomasz Brzoska; Aki Tanaka; Fumiaki Banno; Toshiyuki Miyata; Tetsumei Urano
Journal:  Pflugers Arch       Date:  2011-04-15       Impact factor: 3.657

Review 7.  Regulation of thrombosis and vascular function by protein methionine oxidation.

Authors:  Sean X Gu; Jeff W Stevens; Steven R Lentz
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

Review 8.  Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?

Authors:  Peter F Zipfel; Gunter Wolf; Ulrike John; Karim Kentouche; Christine Skerka
Journal:  Pediatr Nephrol       Date:  2011-06-14       Impact factor: 3.714

9.  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Authors:  Wenjing Cao; Huy P Pham; Lance A Williams; Jenny McDaniel; Rance C Siniard; Robin G Lorenz; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.